Advertisement

Topics

ReNeuron Group (RENE) - Exosomes rise further

15:28 EDT 20 Jul 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron’s capital markets day highlighted the potential for the company’s exosome nanomedicine platform to be a source of both product and licensing revenues. This morning’s announcement of a collaboration between PureTech Health and Roche on PureTech’s milk-derived exosome platform highlights the attractiveness of ReNeuron’s neuronal stem cell-derived exosome platform.
ISIN: GB00BF5G6K95

Original Article: ReNeuron Group (RENE) - Exosomes rise further

NEXT ARTICLE

More From BioPortfolio on "ReNeuron Group (RENE) - Exosomes rise further"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...